Suzanne Gazda

Rituximab in relapsing‐remitting multiple sclerosis: A 72‐week, open‐label, phase I trial

Amit Bar‐Or, Peter A. Calabresi, Douglas L. Arnold et al. · Annals of Neurology · 2008 · 524 citations

Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial

Alasdair Coles, Edward Fox, Anton Vladić et al. · Neurology · 2012 · 260 citations

A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy

Frank Gilliam, Felix Veloso, M.A.M. Bomhof et al. · Neurology · 2003 · 146 citations

Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes

Alasdair Coles, Edward Fox, Anton Vladić et al. · The Lancet Neurology · 2011 · 138 citations

Rheumatology, Clinical Efficacy Outcomes, Autoimmune Disease +9

Long-Term Safety of NGX-4010, a High-Concentration Capsaicin Patch, in Patients with Peripheral Neuropathic Pain

David M. Simpson, Suzanne Gazda, Stephen Brown et al. · Journal of Pain and Symptom Management · 2010 · 104 citations

Pain Therapy, High-concentration Capsaicin Patch, Pain Syndrome +11